FUS and sarcoma: Over 90% of these sarcomas have a pathognomonic t(12;16) (q13;p11) translocation that results in expression of the FUS-DDIT3 fusion protein, whereas they less commonly carry t(12;22), resulting in the expression of the EWSR1-DDIT3 fusion protein.